

<b>Reference Number:</b> UHB141 <b>Version Number:</b> 3	<b>Date of Next Review:</b> 06/02/2023 <b>Previous Trust/LHB Reference Number:</b> T/181
<p align="center"><b>MANAGEMENT OF PARENTERAL CYTOTOXIC CHEMOTHERAPY POLICY</b></p>	
<p><b>Policy Statement</b></p> <p>To ensure the Health Board delivers its aims, objectives, responsibilities and legal requirements transparently and consistently, we will ensure that parenteral cytotoxic chemotherapy is administered safely and that the organisation is compliant with national guidance.</p>	
<p><b>Policy Commitment</b></p> <p>Provide clear guidance to UHB staff about their responsibilities with regard to the use of parenteral cytotoxic chemotherapy in the UHB.</p> <p>The Objectives are</p> <ul style="list-style-type: none"> <li>• To ensure that the interests of the patient, the staff and the UHB are fully protected.</li> <li>• To ensure the safe administration of parenteral cytotoxic chemotherapy to patients in the UHB.</li> <li>• To ensure compliance with national guidelines on prescribing, supply and administration of parenteral cytotoxic chemotherapy.</li> <li>• To provide guidance to UHB staff on the safe administration of parenteral cytotoxic chemotherapy.</li> </ul>	
<p><b>Supporting Procedures and Written Control Documents</b></p> <p>This Policy and the Management of Parenteral Cytotoxic Chemotherapy Procedure (UHB329) describes the facilities required, staff training, prescribing, preparation, administration, and waste management of parenteral cytotoxic chemotherapy.</p> <p><b>Other supporting documents are:</b></p> <p>Procedure for Safe Handling and Administration of Intrathecal Chemotherapy  Guidelines for the Safe Handling, Checking and Administration of Cytotoxics</p>	

Document Title: Management of Parenteral Cytotoxic Chemotherapy Policy	2 of 4	Approval Date: 06 Feb 2020
Reference Number: UHB 141		Next Review Date: 06 Feb 2023
Version Number: 3		Date of Publication: 05 May 2020
Approved By: Medicines Management Group		

## Scope

This policy applies to all of our staff in all locations including those with honorary contracts and applies to intravenous, intra-arterial, intramuscular, subcutaneous, intrathecal, intraventricular, intra-vesical, intravitreal and subconjunctival cytotoxic drugs administered to all patients.

## Equality and Health Impact Assessment

An Equality and Health Impact Assessment (EHIA) has been completed and this found there to be no impact .

***Note: Policies will not be considered for approval without an EHIA***

<b>Policy Approved by</b>	Quality, Safety and Experience Committee
<b>Group with authority to approve procedures written to explain how this policy will be implemented</b>	Medicines Management Group UHB Cytotoxic Chemotherapy Group
<b>Accountable Executive or Clinical Board Director</b>	Medical Director

## Disclaimer

If the review date of this document has passed please ensure that the version you are using is the most up to date either by contacting the document author or the Head Corporate Governance [Sian.Rowlands@wales.nhs.uk](mailto:Sian.Rowlands@wales.nhs.uk)

## Summary of reviews/amendments

Version Number	Date Review Approved	Date Published	Summary of Amendments
1	16/10/2012	19/10/12	Updating following reorganisation replaces previous trust version ref no 181
2	28/06/2016	23/09/2016	Review of document by UHB Cytotoxic Chemotherapy Group and the Medicines Management Group. In line with UHB standards, the original policy has been separated into a stand-alone policy and separate procedures. In addition the need to read the Procedure for Safe Handling and Administration of Intrathecal Chemotherapy has been included within the Procedure.

Document Title: Management of Parenteral Cytotoxic Chemotherapy Policy	3 of 4	Approval Date: 06 Feb 2020
Reference Number: UHB 141		Next Review Date: 06 Feb 2023
Version Number: 3		Date of Publication: 05 May 2020
Approved By: Medicines Management Group		

3	06/02/2020	05/05/2020	Review and update of document by UHB Cytotoxic Chemotherapy Group Inclusion of Guidelines for the Safe Handling, Checking and Administration of Cytotoxics. EHIA completed December 2019

